Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Other Non-Current Assets (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Other Non-Current Assets over the past 10 years, most recently at $212000.0 for Q4 2023.

  • For Q4 2023, Other Non-Current Assets rose 36.47% year-over-year to $212000.0; the TTM value through Dec 2023 reached $212000.0, up 36.47%, while the annual FY2023 figure was $212000.0, 36.47% up from the prior year.
  • Other Non-Current Assets for Q4 2023 was $212000.0 at Corbus Pharmaceuticals Holdings, down from $477425.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $669900.0 in Q4 2020 and troughed at $2614.0 in Q2 2021.
  • A 5-year average of $241000.4 and a median of $144690.0 in 2019 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: crashed 93.08% in 2021 and later surged 18164.15% in 2022.
  • Year by year, Other Non-Current Assets stood at $84968.0 in 2019, then surged by 688.41% to $669900.0 in 2020, then crashed by 93.08% to $46385.0 in 2021, then skyrocketed by 234.91% to $155346.0 in 2022, then surged by 36.47% to $212000.0 in 2023.
  • Business Quant data shows Other Non-Current Assets for CRBP at $212000.0 in Q4 2023, $477425.0 in Q3 2023, and $477425.0 in Q2 2023.